Dr. Karin Halevi-Tobias

Dr Karin Halevi holds a Ph.D. degree in Molecular Biology from the Weizmann Institute of Science Rehovot. Her Ph.D. thesis, in the field of molecular and cellular biology, focused on the proto-oncogene c-Myc as a transcription factor and inducer of apoptosis and on the control of c-Myc degradation. She worked for more than ten years in biotechnology start-up companies in the fields of drug discovery and drug development. Karin joined IMBM in January 2008. At IMBM she takes part in the following two projects:

  1. Modeling of main intracellular signalling pathways controlling stem cell proliferation and differentiation :
    • dynamics of different processes in these pathways for normal tissue homeostasis
    • effects of mutations in these pathways on cancer stem cell development and cancer tissue homeostasis.
  2. Modeling of prostate cancer vaccine:
    • in-trial prediction of the treatment outcome.
    • protocol modification for treatment improvement.

    Work Program for 2010

    • Karin will take part in further development of mathematical models, describing the intracellular pathways responsible for the fate decisions of stem cells and their role in the cancer (with Yuri Kogan and Zvia Agur).
    • Karin will also be involved in developing an algorithm for the prediction of treatment outcomes in clinical trials and in modified treatment protocols—the prostate cancer vaccine model is an example of this application. (with Yuri Kogan, Moran Elishmereni and Zvia Agur)

    Publications

    1. Tobias K.E. & Kahana, C. (1993) Intersubunit location of the active site of mammalian ornithine decarboxylase as determined by hybridization of site-directed mutants. Biochemistry, 32, 5842-5847.
    2. Tobias, K.E., Mamroud-Kidron, E. & Kahana, C. (1993) Gly387 of murine ornithine decarboxylase is essential for the formation of stable homodimers Eur. J. Biochem. 218 , 245-250.
    3. Tobias, K.E., Shor, J. & Kahana, C. (1995) c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs. Oncogene 11, 1721-1727.
    4. Tobias, K.E. & Kahana, C. (1995) -/posure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Cell Growth & Differ. 6 1279-1285.
    5. Gross-Mesilaty, S., Reinstein, E., Bercovich, B., Tobias, K.E., Schwartz , AL., Kahana, C. & Ciechanover, A. (1998) Basel and human papilloma virus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl . Acad. Sci. U S A, 95, 8058-8063.
    6. Sato, S., Kawamura, H., Takemoto, M., Maezawa, Y., Fujimoto, M., Shimoyama, T., Koshizaka, M., Tsurutani, Y., Watanabe, A., Ueda, S., Halevi, K., Saito, Y., Yokote, K. (2009) Biochem Biophys Res Commun. 379, 411–416.


About IMBM | Scientific Board | IMBM Members | Research Projects | Applications
Join Us | Press Release | Events | Publications | HOME